{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:31:09Z","timestamp":1787841069453,"version":"build-2784847793"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Despite huge progress in the fields of newborn screening, encapsulated bacterial infection prophylaxis, immunization, and supportive care in general, people suffering from sickle cell anemia still continue to have a shorter life expectancy and a poorer quality of life due to painful vaso-occlusive events and strokes during childhood, and later, cardiac, pulmonary, and renal injuries, including in Western and high-income countries.<\/jats:p>\n                    <jats:p>From the 2000s, allogeneic stem cell transplantation for severe sickle cell disease from a sibling donor provided the best results-overall as well as disease-free survival-never obtained for any other disease. Nevertheless, this only curative option is proposed to few patient numbers, including in Western countries with high-level medical equipment development, with discrepancies between (i) patients and family, (ii) physicians and care centers dedicated to sickle cell disease, and (iii) hematopoietic stem cell transplant teams.<\/jats:p>\n                    <jats:p>Due to these discrepancies and in order to provide the same quality of discussion and treatment choice for every sickle cell disease patient, we developed a National French multidisciplinary pluri-annual meeting dedicated to sickle cell disease patients and transplantation. We report here our experience of such a meeting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2019.12.013","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T21:57:17Z","timestamp":1588197437000},"page":"58-60","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Hematologist and transplant physicians"],"prefix":"10.4103","volume":"13","author":[{"given":"Jean-Hugues","family":"Dalle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20241211","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N Engl J Med"},{"key":"R2-3-20241211","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2013","journal-title":"Lancet"},{"key":"R3-3-20241211","doi-asserted-by":"crossref","first-page":"e1001484","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010\u20132050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med"},{"key":"R4-3-20241211","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1051\/medsci\/20132911012","article-title":"Sickle-cell disease: geographical distribution and population estimates","volume":"29","author":"Piel","year":"2013","journal-title":"Med Sci (Paris"},{"key":"R5-3-20241211","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1542\/peds.81.6.749","article-title":"Newborn screening for sickle cell disease: effect on mortality","volume":"81","author":"Vichinsky","year":"1988","journal-title":"Pediatrics"},{"key":"R7-3-20241211","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM198606193142501","article-title":"Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial","volume":"314","author":"Gaston","year":"1986","journal-title":"N Engl J Med"},{"key":"R8-3-20241211","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1542\/peds.2007-0018","article-title":"Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life","volume":"121","author":"Adamkiewicz","year":"2008","journal-title":"Pediatrics"},{"key":"R9-3-20241211","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, noninferiority trial","volume":"387","author":"Ware","year":"2016","journal-title":"Lancet"},{"key":"R10-3-20241211","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1056\/NEJMoa050460","article-title":"Optimizing Primary Stroke Prevention in Sickle Cell Anemia Trial I. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease","volume":"353","author":"Adams","year":"2005","journal-title":"N Engl J Med"},{"key":"R11-3-20241211","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM199202273260905","article-title":"The use of transcranial ultrasonography to predict stroke in sickle cell disease","volume":"326","author":"Adams","year":"1992","journal-title":"N Engl J Med"},{"key":"R12-3-20241211","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2010-12-326298","article-title":"Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II","volume":"118","author":"Abboud","year":"2011","journal-title":"Blood"},{"key":"R13-3-20241211","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1182\/blood-2003-06-1972","article-title":"Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study","volume":"103","author":"Abboud","year":"2004","journal-title":"Blood"},{"key":"R14-3-20241211","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979\u20132005","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"key":"R15-3-20241211","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/bmt.2015.65","article-title":"Sickle cell disease is not so benign","volume":"50","author":"Hsieh","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"R16-3-20241211","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2007-03-079665","article-title":"Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease","volume":"110","author":"Bernaudin","year":"2007","journal-title":"Blood"},{"key":"R17-3-20241211","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"key":"R18-3-20241211","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.3324\/haematol.2019.216788","article-title":"Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease","volume":"104","author":"Cappelli","year":"2019","journal-title":"Haematologica"},{"key":"R19-3-20241211","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3324\/haematol.2018.213207","article-title":"Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France","volume":"105","author":"Bernaudin","year":"2019","journal-title":"Haematologica"},{"key":"R21-3-20241211","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620300467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620300467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2019.12.013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:40:59Z","timestamp":1787838059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2019.12.013"}},"subtitle":["How and where to meet for the best of sickle cell disease patients?"],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2019.12.013","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}